News & Views

Telix advises that Associate Professor Brian Shuch, MD, Director, Kidney Cancer Program, UCLA Institute of Urologic Oncology (Los Angeles, California) and a Principal Investigator in the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) will be delivering an oral abstract presentation to the 2023 ASCO GU Symposium being held in San Francisco, CA, on Saturday 18 February at 2.00pm – 2.10pm PDT as the first presentation in the Renal and Rare Tumors session.

Telix today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2022 (Q4 2022). All figures are in AUD$ unless otherwise stated1 and provided on an unaudited basis.

Telix is pleased to provide a webcast recording of CEO and MD Dr. Christian Behrenbruch presenting at the J.P. Morgan Healthcare Conference on Wednesday 11 January 2023.

Telix today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9–12 January) in San Francisco. As part of the Company’s presentation (lodged with this announcement), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.). This is an increase of 39% on Q3 2022, and a total of AU$149.7M (US$100.4M) revenue since Illuccix launch. ASCO GU, the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present the complete results of the ZIRCON trial in detail, including all trial primary and secondary end-points as well as specific grading criteria related to lesion size and detection.

Telix today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation at the upcoming 2023 ASCO GU Symposium to be held in San Francisco, CA, from February 16-18 2023.   ASCO GU, the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present the complete results of the ZIRCON trial in detail, including all trial primary and secondary end-points as well as specific grading criteria related to lesion size and detection.

Telix today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning. 

Telix today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an important development in radioisotope production.

Telix today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM).

Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies London Healthcare Conference in London on Thursday 17 November 2022.

Telix today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials.